A Phase I/II Trial to Evaluate the Safety and Immunogenicity of a Helper Peptide Vaccine Plus CTLA-4 Blockade in Melanoma Patients (Mel62; 6PAC)

Trial Profile

A Phase I/II Trial to Evaluate the Safety and Immunogenicity of a Helper Peptide Vaccine Plus CTLA-4 Blockade in Melanoma Patients (Mel62; 6PAC)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Sep 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Peptide vaccines
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Mel62; 6PAC
  • Most Recent Events

    • 31 Aug 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Aug 2019.
    • 21 Aug 2017 Planned number of patients changed from 51 to 27.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top